SCHEDULE 13D/A: Quanterix Amends Akoya Biosciences Merger Agreement, Securing Majority Shareholder Support

Quanterix Corporation has amended its merger agreement with Akoya Biosciences, Inc., outlining revised acquisition terms and securing voting support from key Akoya shareholders representing 55.6% of outstanding common stock.

Summary

• Quanterix Corporation entered into an Amended and Restated Agreement and Plan of Merger with Akoya Biosciences, Inc. on April 28, 2025, which will result in Akoya becoming a wholly owned subsidiary of Quanterix.
• Each outstanding share of Akoya Common Stock will be converted into 0.1461 shares of Quanterix Common Stock and $0.38 in cash.
• Unvested Akoya Restricted Stock Units (RSUs) will convert into Rollover RSUs, retaining original terms but for the Per Share Merger Consideration, while vested Akoya RSUs will be cancelled for the Per Share Merger Consideration.
• Akoya Options will vest upon the Effective Time; those with an exercise price greater than or equal to the implied merger consideration value will be cancelled for no consideration, while others will be cancelled for Per Share Merger Consideration based on a synthetic cashless exercise.
• Quanterix secured Voting and Support Agreements from 'Supporting Stockholders' of Akoya, who collectively beneficially own 30,560,609 shares, representing approximately 55.6% of Akoya's outstanding common stock as of April 23, 2025.
• These Supporting Stockholders have agreed to vote in favor of the merger and against competing transactions, granting Quanterix an irrevocable proxy.

Sentiment

Score: 8

Explanation: The sentiment is positive as Quanterix has successfully amended its merger agreement and secured significant shareholder support (55.6%) for the acquisition of Akoya Biosciences, indicating strong progress towards closing a strategic transaction. The detailed terms for share and option conversion provide clarity. The only minor caveat is that it's an 'amended and restated' agreement, implying some changes from the original, but the overall tone is one of moving forward with a strategic acquisition.

Positives

• Quanterix has secured voting support from a majority of Akoya's outstanding shares (55.6%), significantly increasing the likelihood of merger approval.
• The merger allows Quanterix to acquire Akoya, expanding its life sciences research and diagnostics capabilities.
• Clear terms for the conversion of Akoya shares, restricted stock units (RSUs), and stock options provide certainty for the transaction participants.

Risks

• The merger is subject to termination conditions as outlined in the Merger Agreement.
• If the Akoya board of directors changes its recommendation regarding the merger, the voting obligations of Supporting Stockholders would be reduced to 35% of outstanding shares, potentially jeopardizing the merger's approval.
• The Akoya Voting Agreements contain specific termination clauses, including potential termination if there are changes to the consideration or an extension of the termination date without the Supporting Stockholders' consent.
• The consummation of the merger depends on obtaining necessary regulatory approvals and satisfying other customary closing conditions.
• The integration of Akoya's operations and personnel into Quanterix may present operational, financial, or cultural challenges.

Future Outlook

Upon consummation of the merger, Akoya Biosciences, Inc. will become a wholly owned subsidiary of Quanterix Corporation. Akoya's common stock will be de-registered from the Securities Exchange Act of 1934, and Quanterix will control Akoya's board of directors, with the ability to make changes to its certificate of incorporation, bylaws, capitalization, management, and business.

Management Comments

• "Neither the filing of this Schedule 13D/A nor any of its contents shall be deemed to constitute an admission by the Reporting Person that it is the beneficial owner of any Akoya Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose, and such beneficial ownership thereof is expressly disclaimed."

Industry Context

This merger signifies a consolidation within the life sciences research and diagnostics sector, where Quanterix, with its proprietary Simoa detection technology, aims to integrate Akoya's capabilities. Such strategic acquisitions are common in the biotech industry to expand product portfolios, market reach, and technological expertise, particularly in areas like protein biomarker detection and advanced immunoassay platforms.

Stakeholder Impact

• Shareholders (Akoya): Will receive a mix of Quanterix stock and cash for their shares, and Akoya's common stock will be de-registered.
• Shareholders (Quanterix): Will experience dilution from the issuance of new shares for the acquisition but will gain Akoya's business and assets.
• Employees (Akoya): Akoya RSUs and options will be converted or cancelled, with unvested RSUs rolling over, impacting their equity compensation. Management and business structure may change post-merger.
• Management (Akoya): Current directors and executive officers of Akoya are among the 'Supporting Stockholders' who entered into voting agreements. Their roles post-merger are not specified, but Quanterix will control the board.

Next Steps

• Quanterix will file a post-effective amendment to its registration statement on Form S-4, which will include a preliminary proxy statement/prospectus.
• Akoya stockholders will vote on the adoption of the Merger Agreement.
• Consummation of the Merger, upon which Akoya will become a wholly owned subsidiary of Quanterix.
• De-registration of Akoya Common Stock under the Securities Exchange Act of 1934.
• Quanterix will control Akoya's board of directors and may make changes to its corporate structure, management, and business.

Key Dates

Keywords

Quanterix Corporation, Akoya Biosciences Inc., Merger Agreement, Acquisition, Schedule 13D/A, Voting Agreement, Life Sciences, Biotechnology, Simoa technology, Common Stock, SEC filing, Corporate Governance, Shareholder Support